A combination of features, including growth phase at the beginning of therapy, the growth velocity during GH therapy and the risk of potential adverse effects of GH therapy (e.g., development of intracranial hypertension, slipped capital femoral epiphysis and scoliosis progression) may determine the specific dosage and duration of the therapy [6, 7]. Here, GH1 is linked to intracranial hypertension.